In early lab models, "NICER" shows promise of targeting both bulk cancer cells and residual cancer cells post-surgery.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback